Scotland first in the UK to recommend the use of Xolair (omalizumab) to treat chronic spontaneous urticaria

Novartis is delighted that the Scottish Medicines Consortium (SMC) has recommended Xolair® omalizumab as an add-on therapy for the treatment of chronic spontaneous urticaria (CSU) in adult and...